

PRESENTED BY:



SPONSORED BY:



CONTINUING MEDICAL EDUCATION

**Pediatric Hematology/Oncology Tumor Board - 5/2/2024 – 62828-59334**

Date: May 2, 2024

Time: 12:00 PM-1:00 PM

UH Cleveland Medical Center

*Duncan Stearns, MD; Rachel Egler, MD  
Case Western Reserve School of Medicine, Rainbow Babies and Children's Hospital*

**Educational Objectives**

At the conclusion of this activity, the participant should be better able to:

- 1 Identify and apply the principles of quality and safety
- 2 Review appropriate therapeutic modalities
- 3 Discuss chemotherapy response
- 4 Evaluate survival and prognostic factors

**Accreditation and Credit Designation Statements**

Case Western Reserve University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Case Western Reserve University School of Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Disclosures:**

All relevant financial relationships have been mitigated. This activity's planners and speaker(s) have made the following disclosures:

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
Duncan Stearns, MD	Co-Director, Course Director, Faculty	Advisor-AstraZeneca (Relationship has ended) Advisor-Tempus labs - 07/06/2023
Breanne Roche, DNP, RN, CPNP	Other Planning Committee Member	Paid consultant-BTG Specialty Pharmaceuticals Speakers Bureau-Alexion - 06/26/2023
Kristen Nagle, CNP, MSN	Other Planning Committee Member	Nothing to disclose - 06/21/2023
Rachel Egler, MD	Co-Director, Course Director, Faculty	Nothing to disclose - 06/01/2023
Melissa Makii, PharmD	Other Planning Committee Member	Paid consultant-Lexicomp Paid consultant-Takeda Pharmaceuticals, Inc. - 05/11/2023